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Abstract
Although it is not generally a life-threatening disease, 
obesity is becoming a major health problem worldwide. 
It can be controlled by means of drugs, and, conse-
quently, these are required to be safe as well as effec-
tive. In this paper, we summarize the fate of various 
drugs that have been introduced for clinical use in the 
treatment of obesity. Fenfluramine and dexfenflura-
mine were withdrawn because of heart valve damage. 
Sibutramine suppresses appetite and increases heart 
rate and blood pressure. In the Sibutramine Cardiovas-
cular OUTcomes trial, an increase in major adverse car-
diovascular events prompted its withdrawal in Europe 
and the United States. Rimonabant is an endocanna-
binoid receptor antagonist that reduces body weight 
and ameliorates some cardiovascular risk factors. Ho-
wever, adverse psychiatric side effects led to its with-
drawal as well. Orlistat is approved in Europe and the 
United States for the treatment of obesity, but its use is 
limited by gastrointestinal side-effects. Ephedrine and 
caffeine are natural ingredients in foods and supple-
ments that may help the person to lose weight. In the 
light of several failed attempts, there is a clear need to 
develop drugs that are effective and safe in the long 
term in order to successfully combat the phenomenon 
of obesity . 
© 2011 Baishideng. All rights reserved.
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INTRODUCTION
Obesity, which is characterized by excess body fat, is a ma­
jor public health problem in many parts of  the world[1,2]. 
The consequences of  obesity are substantial. Obesity 
amplifies the risks of  hypertension, dyslipidaemia, type 2 
diabetes, cardiovascular disease, obstructive sleep apnoea, 
osteoarthritis, and several cancers[3­6]. Obesity is also asso­
ciated with reduced average life expectancy[5]. It is sug­
gested that the treatment of  obesity is a lifelong task, like 
dealing with any other complex disease[7].
In the management of  obesity, lifestyle and behavioral 
modification, including appropriate diet and exercise, 
should be the initial as well as the maintenance treatment 
for obesity; pharmacotherapy is recommended for pa­
tients who are obese, or overweight patients with co­mor­ 
bidities such as type 2 diabetes[8­11]. Anti­obesity drugs 
are classified into three groups, according to their mecha­
nism of  action: appetite suppressants, inhibitors of  fat 
absorption, stimulators of  energy expenditure and ther­
mogenesis[7]. Many medications have been used to treat 
obesity over the years. However, most of  the anti­obesity 
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and Drug Administration (USFDA) and marketed have 
now been withdrawn due to the post­marketing discovery 
of  serious adverse effects. This review summarizes the 
fate of  anti­obesity drugs that have been introduced for 
clinical use (Table 1). 
PHENTERMINE AND FENFLURAMINE
The combination of  phentermine with fenfluramine or 
dexfenfluramine was once commonly used in managing 
obesity. Phentermine is a noradrenergic drug, which sti­
mulates the release of  noradrenaline and reduces food 
intake by acting on β­adrenergic receptors in the perifor­
nical hypothalamus[12]. Fenfluramine and dexfenfluramine 
(the d­isomer of  fenfluramine) are serotonergic drugs, 
which cause the release of  serotonin to suppress appetite 
and reduce food intake [13]. 
Both phentermine and fenfluramine were individually 
approved by the USFDA. The combination of  phen­
termine with fenfluramine or dexfenfluramine was not 
thought to be more effective than either drug alone, 
but lower doses of  each drug could be used in combina­
tion, leading to fewer side effects[14]. However, both fen­
fluramine and dexfenfluramine were withdrawn from 
market by the USFDA in 1997[15]. The decision was pro­
mpted by a preliminary report of  24 women receiving 
fenfluramine[13]. This study identified heart valve damage 
in association with the use of  fenfluramine[13]. Echocar­
diographic and histological findings demonstrated unusual 
valvular morphology that resembled those in carcinoid or 
ergotamine­induced heart valve disease[13]. In this study, 
pulmonary arterial hypertension was also identified in 
eight women[13]. 
SIBUTRAMINE
Sibutramine was widely used after its approval by the 
USFDA in 1997[7,15]. It is a serotonergic and adrenergic 
drug that inhibits the reuptake of  serotonin and norepine­
phrine[16]. Sibutramine is converted to two pharmacologi­
cally active metabolites, N­desmethyl and N­bisdesmethyl 
sibutramine, which are more stable and have a much 
longer half­life compared with sibutramine itself[16]. Sibu­
tramine suppresses appetite, causes satiety, and increases 
thermogenesis mainly through its two active metabo­
lites[16]. 
A meta­analysis showed that sibutramine promoted 
weight loss by about 4.45 kg at 12 mo in overweight and 
obese adults who had a BMI of  25 kg/m2 or greater[17]. In 
a 12­mo study, sibutramine showed potential benefit by 
improving biochemical risk factors associated with obes­
ity, including plasma glucose, insulin, triglycerides, total 
cholesterol, low­density lipoprotein cholesterol (LDL­C) 
and high­density lipoprotein cholesterol (HDL­C)[16]. In 
obese patients, sibutramine was shown to reduce waist cir­
cumference, which is a strong predictor of  cardiovascular 
disease[18,19]. Moreover, sibutramine caused a decrease in 
the level of  glycosylated haemoglobin in obese patients 
with type 2 diabetes[20­22]. In studies lasting 24 wk or less, 
however, there was some regain of  weight after the treat­
ment of  sibutramine stopped[23]. 
The most frequently encountered side effects of  si­
butramine are headache, dry mouth, insomnia, and con­
stipation[24]. Unlike fenfluramine, the use of  sibutramine 
has not been associated with increases in pulmonary hy­
pertension or heart valve damage. However, sibutramine 
increased heart rate and caused a mean of  2 mmHg in­
crease in both diastolic and systolic blood pressure at a 
dose of  10­15 mg daily in some patients[16]. The increase 
in blood pressure was more pronounced in patients who 
were younger and more obese[16]. In some other placebo­
controlled trials, sibutramine did not increase blood pres­
sure in either normotensive individuals or hypertensive 
patients[25]. Moreover, in a study of  6 mo in duration, 
the sibutramine/sustained release verapamil/trandolapril 
combination significantly reduced blood pressure and 
improved total cholesterol, HDL­C and triglycerides com­
pared with the sustained release verapamil/trandolapril 
combination in obese hypertensive patients[26]. Therefore, 
the influence of  sibutramine on the sympathetic nervous 
system might be more complicated than previously be­
lieved. The effect of  sibutramine treatment on sympathet­
ic vasomotor tone in obese patients has been studied[27]. It 
was found that the balance between peripheral stimulation 
and central inhibition on the sympathetic nervous system 
determined the net change in blood pressure, which might 
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Table 1  Anti-obesity drugs[7]
Drug Mechanism of action Effect on weight Side effects
Phentermine Reducing food intake: sympathomimetic 
amine
3.6 kg at 6 mo Headache, insomnia, irritability, palpitations and nervousness
Diethylpropion As above 3.0 kg at 6 mo As above
Fluoxetine Reducing food intake: selective serotonin 
reuptake inhibitor
4.74 kg at 6 mo, and 3.15 kg 
at 1 year
Agitation and nervousness
Sibutramine Reducing food intake: combined 
norepinephrine and serotonin reuptake 
inhibitor
4.45 kg at 1 year Headache, insomnia, dry mouth and constipation.  Long term 
treatment increases the risk of major adverse cardiovascular 
events
Orlistat Reducing fat absorption: lipase inhibitor 2.59 kg at 6 mo and 2.89 kg 
at 1 year
Diarrhoea, flatulence, bloating, abdominal pain and dyspepsia
Rimonabant Reducing food intake: selective CB1 
receptor blocker
5.1 kg at 1 year Nausea, dizziness, arthralgia and diarrhoea
vary in different circumstances[27]. Due to the concern 
over blood pressure, sibutramine is not recommended for 
use in patients with coronary heart disease, cardiac arrhy­
thmias, uncontrolled hypertension, congestive heart fail­
ure, or a history of  stroke. 
The 5­year Sibutramine Cardiovascular OUTcomes 
(SCOUT) trial was a randomized, double­blind and pla­
cebo­controlled study involving 10 742 overweight or 
obese patients with cardiovascular disease, hypertension 
or type 2 diabetes[28]. After a 6­wk lead­in period, patients 
who received single­blind sibutramine had, on average, 
a 2.2 kg reduction of  body weight, a 2.0 cm reduction 
of  waist circumference, a 3.0 mmHg decrease in systolic 
blood pressure, a 1.0 mmHg decrease in diastolic blood 
pressure, and a 1.5 bpm decrease in pulse rate[28]. In ad­
dition, sibutramine was found to be efficacious, tolerable 
and safe in this 6­wk single­blind period[28]. In January 
2010, a preliminary report of  the SCOUT study, which 
showed that sibutramine was associated with an increased 
risk of  serious, non­fatal cardiovascular events such as 
myocardial infarction or stroke as compared with placebo 
(11.4% vs 10%, hazard ratio, 1.16; 95% confidence inter­
val, 1.03­1.31), led to the recommendation to suspend the 
use of  sibutramine by the Committee for Medicinal Prod­
ucts (CHMP) for Human Use of  the European Medicine 
Agency (EMEA)[29,30]. Sibutramine has subsequently been 
withdrawn from the European market[30]. The USFDA 
requested that healthcare professionals be notified that 
sibutramine should not be used in patients with known 
cardiovascular disease[29]. The full results of  the SCOUT 
study were published in September 2010[31]. Long­term 
sibutramine treatment was shown to increase the risk of  
nonfatal myocardial infarction and nonfatal stroke, but 
not of  cardiovascular death or death from any cause, in 
overweight or obese patients with pre­existing cardiovas­
cular diseases. The USFDA decided that the drug might 
pose unnecessary cardiovascular risks to patients, and so 
sibutramine was withdrawn on 8 October 2010[32].
RIMONABANT
The endocannabinoid system has been identified as play­
ing a significant role in the control of  food intake and 
energy balance, as well as lipid and glucose metabolism[33]. 
Endocannabinoids act as endogenous ligands capable of  
activating two types of  G protein­coupled cannabinoid 
receptors, the cannabinoid type 1 (CB1) receptor and the 
cannabinoid type 2 (CB2) receptor[34]. The CB1 receptor is 
expressed in the central nervous system and in peripheral 
tissues such as adipose tissue, the gastrointestinal tract, 
the liver and muscle, which are all involved in lipid and 
glucose metabolism[35]. The CB2 receptor is located in the 
immune and hematopoietic cells[35]. Prior studies have 
demonstrated that the endocannabinoid system is over­
active in obesity, suggesting that weight loss could be 
induced and metabolic profiles improved if  the elevated 
endocannabinoid tone is possibly suppressed[36]. Rimo­
nabant, the first drug selectively antagonizing the CB1 
receptor in the brain and in the periphery, is aimed at fight­
ing obesity and associated risk factors[37]. The approval 
of  rimonabant was recommended by the CHMP of  the 
EMEA in April 2006[7]. 
Thus far, there have been four large human clinical trials 
that tested the safety and efficacy of  rimonabant[34,38­40]. 
The rimonabant in obesity (RIO) Europe trial and the 
RIO­North America trial included obese patients or 
overweight patients with obesity­induced disease. The 
RIO­Lipids and RIO­Diabetes trials included patients 
with hyperlipidaemia and type 2 diabetes, respectively. 
All these four randomized, double­blinded, placebo­
controlled trials of  rimonabant showed similar effects of  
rimonabant on weight loss and cardiovascular risk factors. 
Rimonabant promoted weight loss by about 4.7 kg at 
1­year follow­up[35]. However, it was later reported that 
use of  rimonabant was associated with psychiatric side 
effects including anxiety, depression and suicidal ideation. 
These adverse psychiatric events were observed in 26% 
of  the participants in 20 mg rimonabant group compared 
with 14% of  those on placebo in the same four studies[41]. 
In October 2008, despite the extensive clinical trial data, 
the suspension of  rimonabant was recommended by the 
EMEA[7]. Permission for the use of  rimonabant was also 
declined by the USFDA[35].
ORLISTAT
Orlistat, a reversible gastrointestinal lipase inhibitor, is ap­
proved for the long­term management of  obesity. Orlistat 
reduces calorie intake and leads to weight loss by inhibit­
ing hydrolyzation of  dietary fat in the gut and reducing its 
absorption[42]. In a meta­analysis of  29 studies, orlistat re­
duced body weight by about 2.59 kg at 6 mo and about 2.89 
kg at 12 mo[43]. When compared to treatment with placebo 
and diet, orlistat significantly reduced waist circumfer­
ence, total cholesterol, LDL­C and blood pressure, and 
improved blood glucose levels and insulin resistance[44­47]. 
In practice, the most common side effects of  orlistat af­
fect the digestive system, and include diarrhea, flatulence, 
bloating, abdominal pain and dyspepsia[48]. Orlistat may 
not be well tolerated as a result of  these side­effects which 
are related to the unabsorbed fat in the intestine. In ad­
dition, long­term use of  orlistat can result in a deficiency 
of  the fat­soluble vitamins (vitamin A, D, E, and K). Ad­
equate vitamin supplementation may therefore be needed 
for patients on orlistat. It should be remembered that 
there are very limited data on the long term effects of  or­
listat on cardiovascular outcomes.
EPHEDRINE AND CAFFEINE 
Ephedrine and caffeine belong to the category of  drugs 
that increase energy expenditure and thermogenesis. In 
a long­term placebo­controlled clinical trial, the com­
bination of  ephedrine and caffeine showed a greater effect 
on weight loss than either when used alone. These sub­
stances are contained in some health supplements. How­
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ever, to date, the combination of  ephedrine and caffeine 
has not been approved as an anti­obesity treatment[12].
OTHER ANTI-OBESITY DRUGS
There are three other drugs that show promise but are 
not yet licensed for the treatment of  obesity. Metformin 
has been used for many years in patients with type 2 
diabetes mellitus. It is the only anti­diabetic drug that 
has been shown, in long term clinical trials, to reduce 
mortality and to prevent the development of  diabetes[49]. 
Unlike sulphonylureas and insulin, it does not cause wei­
ght gain. In some studies, weight reduction has been 
observed among non­diabetic individuals. Metformin is 
not currently licensed for the treatment of  obesity, but 
it is a first line treatment in patients with type 2 diabetes, 
especially if  they are obese. 
Topiramate is an anti­epileptic drug that blocks volt­
age­dependent sodium channels, glutamate receptors, and 
carbonic anhydrase, and augments the activity of  gamma­
aminobutyrate (GABA). It remains unlicensed for the 
treatment of  obesity because diarrhoea and leakage were 
observed in early clinical studies. Qnexa is a combination 
of  topiramate and phentermine[50]. The combination is 
better tolerated and it causes impressive weight reduction. 
The USFDA has not approved it yet, the outstanding 
concerns being possible effects on the fetus in women of  
childbearing age and an increase in heart rate.
Liraglutide, like exenatide, is a glucagon­like peptide­1 
(GLP­1) analogue that was first used for the treatment 
of  type 2 diabetes mellitus. As GLP­1 suppresses appe­
tite and delays gastric emptying, liraglutide reduces body 
weight, even in non­diabetic individuals[51].
CONCLUSION
Despite promising results on body weight reduction and 
some cardiovascular risk factors, most anti­obesity drugs 
developed so far have not been approved or have had to 
be withdrawn from the market, due to adverse side effects. 
As sibutramine is no longer available, orlistat is currently 
the only anti­obesity drug to have been approved for 
long­term use[15]. The development of  new anti­obesity 
drugs is therefore urgently needed. The long­term safety 
and efficacy of  newly­developed drugs should be carefully 
evaluated. It should also be mentioned that most clinical 
trials tested anti­obesity drugs in combination with a 
reduced calorie diet. Since compliance is usually better in 
clinical studies, the weight reduction in clinical practice 
might be smaller.
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